Avecho Biotechnology Limited (AU:AVE) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Avecho Biotechnology Limited has launched a Phase III clinical trial for its novel oral CBD TPM-enhanced soft-gel capsule aimed at treating insomnia, marking a significant step towards potentially becoming the first over-the-counter CBD-based insomnia treatment in Australia. The study, which is the largest of its kind, will involve 519 patients across multiple cities, testing nightly doses of CBD over an 8-week period. The trial’s success would enable the company to apply for pharmaceutical registration and capitalize on recent regulatory changes allowing over-the-counter sales of CBD products in Australia.
For further insights into AU:AVE stock, check out TipRanks’ Stock Analysis page.
